Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
Abstract Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Neverth...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13953 |
| _version_ | 1818458663861354496 |
|---|---|
| author | Vito Longo Annamaria Catino Michele Montrone Pamela Pizzutilo Francesco Pesola Ilaria Marech Iolanda Capone Arsela Prelaj Domenico Galetta |
| author_facet | Vito Longo Annamaria Catino Michele Montrone Pamela Pizzutilo Francesco Pesola Ilaria Marech Iolanda Capone Arsela Prelaj Domenico Galetta |
| author_sort | Vito Longo |
| collection | DOAJ |
| description | Abstract Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Nevertheless, some uncommon mutations do confer sensitivity to tyrosine kinase inhibitors (TKIs) which is comparable with common mutations. In particular, some compound EGFR mutations seem to be characterized by a favorable prognosis. Unfortunately, the rarity of complex EGFR mutations results in difficult clinical decision‐making. Herein, to the best of our knowledge, we report the first case of an NSCLC patient with an EGFR triple mutation containing T785A/L861Q/H297_E298 who was successfully treated with afatinib. |
| first_indexed | 2024-12-14T23:02:03Z |
| format | Article |
| id | doaj.art-35e214ab38604b83854e2e888b4bfc36 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-14T23:02:03Z |
| publishDate | 2021-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-35e214ab38604b83854e2e888b4bfc362022-12-21T22:44:26ZengWileyThoracic Cancer1759-77061759-77142021-07-0112132031203410.1111/1759-7714.13953Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinibVito Longo0Annamaria Catino1Michele Montrone2Pamela Pizzutilo3Francesco Pesola4Ilaria Marech5Iolanda Capone6Arsela Prelaj7Domenico Galetta8Medical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyPathology and Laboratory Medicine Department Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan ItalyMedical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan ItalyMedical Thoracic Oncology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari ItalyAbstract Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mutations; exon 19 deletion, and exon 21 L858R. Nevertheless, some uncommon mutations do confer sensitivity to tyrosine kinase inhibitors (TKIs) which is comparable with common mutations. In particular, some compound EGFR mutations seem to be characterized by a favorable prognosis. Unfortunately, the rarity of complex EGFR mutations results in difficult clinical decision‐making. Herein, to the best of our knowledge, we report the first case of an NSCLC patient with an EGFR triple mutation containing T785A/L861Q/H297_E298 who was successfully treated with afatinib.https://doi.org/10.1111/1759-7714.13953compound EGFR mutationskinase inhibitorstyrosineuncommon EGFR mutations |
| spellingShingle | Vito Longo Annamaria Catino Michele Montrone Pamela Pizzutilo Francesco Pesola Ilaria Marech Iolanda Capone Arsela Prelaj Domenico Galetta Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib Thoracic Cancer compound EGFR mutations kinase inhibitors tyrosine uncommon EGFR mutations |
| title | Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib |
| title_full | Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib |
| title_fullStr | Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib |
| title_full_unstemmed | Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib |
| title_short | Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib |
| title_sort | successful treatment of triple egfr mutation t785a l861q h297 e298 with afatinib |
| topic | compound EGFR mutations kinase inhibitors tyrosine uncommon EGFR mutations |
| url | https://doi.org/10.1111/1759-7714.13953 |
| work_keys_str_mv | AT vitolongo successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT annamariacatino successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT michelemontrone successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT pamelapizzutilo successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT francescopesola successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT ilariamarech successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT iolandacapone successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT arselaprelaj successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib AT domenicogaletta successfultreatmentoftripleegfrmutationt785al861qh297e298withafatinib |